{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T01:37:27Z","timestamp":1768441047988,"version":"3.49.0"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T00:00:00Z","timestamp":1650844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>Aicardi-Gouti\u00e8res syndrome (AGS) is a rare hereditary early-onset encephalopathy. The syndrome was first described in 1984, and is characterised by upregulation of the type I interferon (IFN) pathway, which is involved in the host immune response against viral infections, including SARS-CoV-2. Whilst defects in type I IFN pathways have been described in association with severe coronavirus disease 2019 (COVID-19), less is known about the outcomes of upregulation. We describe an unusual case of generalised panniculitis as a post-COVID-19 phenomenon in a child with AGS. Our patient was initially managed with systemic steroid therapy, but due to relapse of symptoms on weaning, an alternative therapy was sought. In this case, a novel use of ruxolitinib, a JAK inhibitor, has resulted in lasting remission without complications. We discuss the probable protective role of IFN upregulation following COVID-19 infection in AGS and possible immunological mechanisms driving the panniculitis and therapeutic response in our case.<\/jats:p>","DOI":"10.3389\/fped.2022.837568","type":"journal-article","created":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T11:01:39Z","timestamp":1650884499000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Case Report: Generalised Panniculitis as a Post-COVID-19 Presentation in Aicardi-Gouti\u00e8res Syndrome Treated With Ruxolitinib"],"prefix":"10.3389","volume":"10","author":[{"given":"Abirami","family":"Pararajasingam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel E.","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Evans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashima","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Goodwin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Jolles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/ana.410150109","article-title":"A progressive familial encephalopathy in infancy with calcifications of the basal ganglia and chronic cerebrospinal fluid lymphocytosis.","volume":"15","author":"Aicardi","year":"1984","journal-title":"Ann Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/0022-510x(88)90125-6","article-title":"Intrathecal synthesis of interferon-alpha in infants with progressive familial encephalopathy.","volume":"84","author":"Lebon","year":"1988","journal-title":"J Neurol Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/S1474-4422(13)70258-8","article-title":"Assessment of interferon-related biomarkers in Aicardi-Gouti\u00e8res syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study.","volume":"12","author":"Rice","year":"2013","journal-title":"Lancet Neurol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1038\/s41588-020-00737-3","article-title":"cGAS-mediated induction of type I interferon due to inborn errors of histone pre-mRNA processing.","volume":"52","author":"Uggenti","year":"2020","journal-title":"Nat Genet."},{"key":"B5","first-page":"551","article-title":"Studies on the production, mode of action and properties of interferon.","volume":"38","author":"Lindenmann","year":"1957","journal-title":"Br J Exp Pathol."},{"key":"B6","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1098\/rspb.1957.0048","article-title":"Virus interference. I. the interferon.","volume":"147","author":"Isaacs","year":"1957","journal-title":"Proc R Soc Lond B Biol Sci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.autrev.2017.07.001","article-title":"Does type-I interferon drive systemic autoimmunity?","volume":"16","author":"Picard","year":"2017","journal-title":"Autoimmun Rev."},{"key":"B8","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1093\/bmb\/ldn049","article-title":"Aicardi\u2013Gouti\u00e8res syndrome.","volume":"89","author":"Orcesi","year":"2009","journal-title":"Brit Med Bull."},{"key":"B9","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1136\/jmg.40.3.183","article-title":"Cree encephalitis is allelic with Aicardi-Gouti\u00e9res syndrome: implications for the pathogenesis of disorders of interferon alpha metabolism.","volume":"40","author":"Crow","year":"2003","journal-title":"J Med Genet."},{"key":"B10","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/nri3850","article-title":"Aicardi-Gouti\u00e8res syndrome and the type I interferonopathies.","volume":"15","author":"Crow","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1055\/s-0036-1592307","article-title":"Neurologic phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR1, and IFIH1: Aicardi-Goutieres syndrome and beyond.","volume":"47","author":"Livingston","year":"2016","journal-title":"Neuropediatrics."},{"key":"B12","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.coi.2018.09.017","article-title":"SAMHD1 and the innate immune response to cytosolic DNA during DNA replication.","volume":"56","author":"Coquel","year":"2019","journal-title":"Curr Opin Immunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1086\/521373","article-title":"Clinical and molecular phenotype of Aicardi-Goutieres syndrome.","volume":"81","author":"Rice","year":"2007","journal-title":"Am J Hum Genet."},{"key":"B14","first-page":"822","article-title":"[Clinical and genetic analysis of a family with Aicardi-Gouti\u00e8res syndrome and literature review].","volume":"52","author":"Ji","year":"2014","journal-title":"Zhonghua Er Ke Za Zhi."},{"key":"B15","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.braindev.2003.12.011","article-title":"Aicardi\u2013Gouti\u00e8res syndrome.","volume":"27","author":"Gouti\u00e8res","year":"2005","journal-title":"Brain Dev."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1212\/01.WNL.0000159864.05826.08","article-title":"The natural history of Aicardi-Gouti\u00e8res syndrome: follow-up of 11 Italian patients.","volume":"64","author":"Lanzi","year":"2005","journal-title":"Neurology."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.cell.2020.04.026","article-title":"Imbalanced host response to SARS-CoV-2 drives development of COVID-19.","volume":"181","author":"Blanco-Melo","year":"2020","journal-title":"Cell."},{"key":"B18","doi-asserted-by":"publisher","first-page":"E3798","DOI":"10.1073\/pnas.1801213115","article-title":"SAMHD1 suppresses innate immune responses to viral infections and inflammatory stimuli by inhibiting the NF-kappaB and interferon pathways.","volume":"115","author":"Chen","year":"2018","journal-title":"Proc Natl Acad Sci USA."},{"key":"B19","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/bjd.19163","article-title":"Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases.","volume":"183","author":"Galv\u00e1n Casas","year":"2020","journal-title":"Br J Dermatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.berh.2017.12.002","article-title":"Genetic interferonopathies: an overview.","volume":"31","author":"Eleftheriou","year":"2017","journal-title":"Best Pract Res Clin Rheumatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.jaci.2020.09.010","article-title":"Coronavirus disease 2019 in patients with inborn errors of immunity: an international study.","volume":"147","author":"Meyts","year":"2020","journal-title":"J Allergy Clin Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"108743","DOI":"10.1016\/j.clim.2021.108743","article-title":"IFN-\u03b1 levels in ruxolitinib-treatead Aicardi-Gouti\u00e8res patient during SARS-CoV-2 infection: a case report.","volume":"227","author":"Badolato","year":"2021","journal-title":"Clin Immnol (Orlando Fla)."},{"key":"B23","doi-asserted-by":"publisher","first-page":"eabd4570","DOI":"10.1126\/science.abd4570","article-title":"Inborn errors of type I IFN immunity in patients with life-threatening COVID-19.","volume":"370","author":"Zhang","year":"2020","journal-title":"Science."},{"key":"B24","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1126\/science.abc6027","article-title":"Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients.","volume":"369","author":"Hadjadj","year":"2020","journal-title":"Science."},{"key":"B25","doi-asserted-by":"publisher","first-page":"eabd4585","DOI":"10.1126\/science.abd4585","article-title":"Autoantibodies against type I IFNs in patients with life-threatening COVID-19.","volume":"370","author":"Bastard","year":"2020","journal-title":"Science (New York N.Y)."},{"key":"B26","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1002\/iid3.404","article-title":"Age-related differences in the immune response could contribute to determine the spectrum of severity of COVID-19.","volume":"9","author":"ostagliola","year":"2021","journal-title":"Immun Inflamm Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"732.e","DOI":"10.1016\/j.jaci.2021.06.024","article-title":"Mechanisms underlying genetic susceptibility to multisystem inflammatory syndrome in children (MIS-C).","volume":"148","author":"Chou","year":"2021","journal-title":"J Allergy Clin Immunol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12969-016-0094-4","article-title":"Type I interferonopathies in pediatric rheumatology.","volume":"14","author":"Volpi","year":"2016","journal-title":"Pediatr Rheumatol Online J."},{"key":"B29","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.jaad.2020.05.145","article-title":"Chilblain-like acral lesions during the COVID-19 pandemic (\u201dCOVID toes\u201d): Histologic, immunofluorescence, and immunohistochemical study of 17 cases.","volume":"83","author":"Kanitakis","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1210\/jc.2010-0488","article-title":"An autosomal recessive syndrome of joint contractures, muscular atrophy, microcytic anemia, and panniculitis-associated lipodystrophy.","volume":"95","author":"Garg","year":"2010","journal-title":"J Clin Endocrinol Metab."},{"key":"B31","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1001\/jamadermatol.2020.4324","article-title":"Clinical, laboratory, and interferon-alpha response characteristics of patients with chilblain-like lesions during the COVID-19 pandemic.","volume":"157","author":"Hubiche","year":"2021","journal-title":"JAMA Dermatol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1111\/bjd.19483","article-title":"Negative tests for SARS-CoV-2 infection do not rule out its responsibility for chilblains.","volume":"183","author":"Battesti","year":"2020","journal-title":"Br J Dermatol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/j.jaad.2020.06.1018","article-title":"New insights in COVID-19-associated chilblains: a comparative study with chilblain lupus erythematosus.","volume":"83","author":"Battesti","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/ajh.2830440320","article-title":"Cutaneous necrosis caused by injection of alpha-interferon in a patient with chronic myelogenous leukemia.","volume":"44","author":"Oeda","year":"1993","journal-title":"Am J Hematol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1046\/j.1365-2133.1996.d01-1028.x","article-title":"Raynaud\u2019s phenomenon and digital necrosis induced by interferon-alpha.","volume":"135","author":"Bachmeyer","year":"1996","journal-title":"Br J Dermatol."},{"key":"B36","first-page":"194","article-title":"Panniculitis after subcutaneous injection of interferon beta in a multiple sclerosis patient.","volume":"12","author":"Heinzerling","year":"2002","journal-title":"Eur J Dermatol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1136\/jnnp.2006.094813","article-title":"Panniculitis and lipoatrophy after subcutaneous injection of interferon beta-1b in a patient with multiple sclerosis.","volume":"77","author":"O\u2019Sullivan","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B38","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1001\/archdermatol.2009.106","article-title":"Interferon beta-induced panniculitis mimicking acute appendicitis.","volume":"145","author":"Poulin","year":"2009","journal-title":"Arch Dermatol."},{"key":"B39","first-page":"640","article-title":"Pegylated interferon Alpha2a induced panniculitis in patient with chronic hepatitis C.","volume":"50","author":"Baek","year":"2012","journal-title":"Korean J Dermatol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/1346-8138.12389","article-title":"Disseminated ulcerating lupus panniculitis emerging under interferon therapy of hairy cell leukemia: treatment- or disease-related?","volume":"41","author":"Urosevic-Maiwald","year":"2014","journal-title":"J Dermatol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"272","DOI":"10.4166\/kjg.2016.67.5.272","article-title":"Repeated Panniculitis Induced by Pegylated Interferon Alpha 2a in a Patient with Chronic Hepatitis C.","volume":"67","author":"Song","year":"2016","journal-title":"Korean J Gastroenterol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1194.e","DOI":"10.1016\/j.jaci.2020.07.033","article-title":"Immune dysregulation and multisystem inflammatory syndrome in children (MIS-C) in individuals with haploinsufficiency of SOCS1.","volume":"146","author":"Lee","year":"2020","journal-title":"J Allergy Clin Immunol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"A59","DOI":"10.1053\/ejpn.2002.0576","article-title":"Aicardi\u2013Goutie\u2018res syndrome: immunophenotyping in relation to interferon-alpha.","volume":"6","author":"Kuijpers","year":"2002","journal-title":"Eur J Paediatr Neurol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.ejpn.2007.10.005","article-title":"Aicardi-Gouti\u00e8res syndrome presenting atypically as a sub-acute leukoencephalopathy.","volume":"12","author":"Orcesi","year":"2008","journal-title":"Eur J Paediatr Neurol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1111\/j.1469-8749.2008.03033.x","article-title":"Aicardi-Gouti\u00e8res syndrome: description of a late onset case.","volume":"50","author":"D\u2019Arrigo","year":"2008","journal-title":"Dev Med Child Neurol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1055\/s-2005-873058","article-title":"Phenotypic overlap between infantile systemic lupus erythematosus and Aicardi\u2013Goutie\u2018res syndrome.","volume":"36","author":"De Laet","year":"2005","journal-title":"Neuropediatrics."},{"key":"B47","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ymgme.2019.02.006","article-title":"Spontaneous MRI improvement and absence of cerebral calcification in Aicardi-Gouti\u00e8res syndrome: diagnostic and disease-monitoring implications.","volume":"126","author":"Tonduti","year":"2019","journal-title":"Mol Gen Met."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/j.jaci.2016.07.015","article-title":"Efficacy of the Janus kinase 1\/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children.","volume":"138","author":"Fr\u00e9mond","year":"2016","journal-title":"J Allergy Clin Immunol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1007\/s10875-018-0563-2","article-title":"JAK 1\/2 Blockade in MDA5 Gain-of-Function.","volume":"38","author":"McLellan","year":"2018","journal-title":"J Clin Immunol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1212\/WNL.0000000000004921","article-title":"An open-label trial of JAK 1\/2 blockade in progressive IFIH1-associated neuroinflammation.","volume":"90","author":"Kothur","year":"2018","journal-title":"Neurology."},{"key":"B51","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1136\/annrheumdis-2018-214037","article-title":"Efficacy of JAK1\/2 inhibition in the treatment of chilblain lupus due to TREX1 deficiency.","volume":"78","author":"Briand","year":"2019","journal-title":"Ann Rheum Dis."},{"key":"B52","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1056\/NEJMoa1905633","article-title":"JAK inhibitor therapy in a child with inherited USP18 deficiency.","volume":"382","author":"Alsohime","year":"2020","journal-title":"N Engl J Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1172\/JCI98814","article-title":"JAK1\/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies.","volume":"128","author":"Sanchez","year":"2018","journal-title":"J Clin Invest."}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.837568\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T11:01:49Z","timestamp":1650884509000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.837568\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,25]]},"references-count":53,"alternative-id":["10.3389\/fped.2022.837568"],"URL":"https:\/\/doi.org\/10.3389\/fped.2022.837568","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,25]]},"article-number":"837568"}}